Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Falling Stocks: What is Going on With Corvus Pharmaceuticals Inc (CRVS)?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares have fallen 50% in mid-day trading after the company announced interim results from an ongoing phase 1/1b study demonstrating safety and clinical activity of lead checkpoint inhibitor CPI-444 in patients with advanced cancers. Although the data showed that treatment with CPI-444 as a single agent and in combo with Tecentriq was ‘was well tolerated and resulted in anti-tumor activity in patients with multiple types of advanced solid tumors, including those resistant or refractory to prior treatment with anti-PD-1 or anti-PD-L1 antibodies’, the market evidently didn’t like certain numbers in the study as traders were expecting better results. PI-444 is a selective and potent inhibitor of the adenosine A2A receptor.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

According to our data, the number of elite funds long Corvus Pharmaceuticals Inc (NASDAQ:CRVS) rose by one quarter-over-quarter to 6 at the end of December.

The Bottom Line

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares are down after the company released interim results from an ongoing phase 1/1b study. Evidently the market was expecting better results than what actually occurred. For further reading, check out the article, ‘10 Most Popular Stocks Among Hedge Funds‘.

Follow Corvus Pharmaceuticals Inc.
Trade (CRVS) Now!




DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.